FibroGen (NASDAQ:FGEN) initiated with Neutral rating and $45 (10% upside) price target at Bank of America.
Salarius Pharmaceuticals (NASDAQ:SLRX) initiated with Buy rating at Ladenburg Thalmann. Shares up 13% premarket.
LabCorp (NYSE:LH) upgraded to Buy with a $214 (31% upside) price target at Citigroup. Shares up 4% premarket.
Quest Diagnostics (NYSE:DGX) upgraded to Buy with a $130 (21% upside) price target at Citi. Shares up 3% premarket.
Surgery Partners (NASDAQ:SGRY) upgraded to Buy with a $14 (40% upside) price target at Benchmark. Shares up 3% premarket.
Abiomed (ABMd) downgraded to Market Perform with a $175 (4% upside) price target at SVB Leerink.
Cronos Group (CRON CN) downgraded to Market Perform with a C$9.17 (5% upside) price target at Raymond James. Shares (NASDAQ:CRON) up a fraction in U.S.
Gilead Sciences (NASDAQ:GILD) downgraded to Neutral with an $80 (flat) price target at UBS. Shares up 1% premarket.
https://seekingalpha.com/news/3564582-citi-bullish-on-reference-labs-in-premarket-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.